Donald Hayden
Chairman at AVANIR PHARMACEUTICALS INC
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Bradley Campbell | M | 48 | 18 years | |
| Will Lewis | M | 55 | 12 years | |
| S. Schaeffer | F | 55 | 19 years | |
| Sandra Leung | F | 63 | 32 years | |
| Alexandra Glucksmann | M | 65 | 6 years | |
| Al Altomari | M | 65 | 12 years | |
| Ellen Rosenberg | F | 61 | 8 years | |
| Drayton Wise | M | 49 | 10 years | |
| Roger Adsett | M | 55 | 8 years | |
| Eugene Jeffrey Sullivan | M | 59 | 9 years | |
| Yao Lee | M | 54 | 6 years | |
| Elizabeth Anderson | F | 66 | 6 years | |
| Shiva G. Fritsch | F | - | 7 years | |
| Kimberly Noonan | M | - |
WindMIL Therapeutics, Inc.
 WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | 8 years |
| Karen LaRochelle | F | 58 |
WindMIL Therapeutics, Inc.
WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | 25 years |
| Edward Stelmakh | M | 58 |
Otsuka America Pharmaceutical, Inc.
 Otsuka America Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Otsuka America Pharmaceutical, Inc. manufactures and supplies pharmaceutical products. It develops drugs for neuroscience, cardiovascular, and gastrointestinal treatments. The company was founded in 1989 and is headquartered in Rockville, MD. | - |
| Michael Smith | M | 47 | 10 years | |
| Kimberly McCutcheon Jablonski | F | - | 21 years | |
| Kelly Parker | M | - | 9 years | |
| Ram Palanki | M | 48 | 6 years | |
| Kabir Kumar Nath | M | 59 |
Otsuka America Pharmaceutical, Inc.
Otsuka America Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Otsuka America Pharmaceutical, Inc. manufactures and supplies pharmaceutical products. It develops drugs for neuroscience, cardiovascular, and gastrointestinal treatments. The company was founded in 1989 and is headquartered in Rockville, MD. | 8 years |
| Daniel Tassé | M | 64 | 8 years | |
| David Stump | M | 74 | 9 years | |
| Glenn Sblendorio | M | 68 | 18 years | |
| Robert McQuade | M | 67 |
Otsuka America Pharmaceutical, Inc.
Otsuka America Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Otsuka America Pharmaceutical, Inc. manufactures and supplies pharmaceutical products. It develops drugs for neuroscience, cardiovascular, and gastrointestinal treatments. The company was founded in 1989 and is headquartered in Rockville, MD. | - |
| Craig Wheeler | M | 63 | 8 years | |
| Argeris Karabelas | M | 71 | 9 years | |
| David McGirr | M | 69 | 11 years | |
| Lynn Bleil | F | 60 | 6 years | |
| David Brennan | M | 70 | 10 years | |
| Curran Simpson | M | 62 | 9 years | |
| Margaret McGlynn | F | 64 | 15 years | |
| David Clark | M | 49 | 6 years | |
| Patrick Christmas | M | 53 | 8 years | |
| Brian H. Dovey | M | 83 |
WindMIL Therapeutics, Inc.
WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | - |
| Daniel O’Donnell | M | - |
WindMIL Therapeutics, Inc.
WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | - |
| Mark McDade | M | 69 |
WindMIL Therapeutics, Inc.
WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | - |
| Anna Phil | M | 36 |
WindMIL Therapeutics, Inc.
WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | 6 years |
| Dan Dalton | M | - | 8 years | |
| Aneta Ferguson | F | - | 9 years | |
| Howard Soule | M | - |
WindMIL Therapeutics, Inc.
WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | - |
| Patrick Dougherty | M | - |
WindMIL Therapeutics, Inc.
WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | 6 years |
| Stephen Pakola | M | 55 | 5 years | |
| Jerome W. Jackson | M | - | 9 years | |
| Stephen M. Kaufhold | M | - | 8 years | |
| Patrik Florencio | M | - | 9 years | |
| Hisanori Maei | M | - | 9 years | |
| Thomas DesRosier | M | 69 | - | |
| Walter R. Perkins | M | - | 14 years | |
| Diana Moore | F | - | 9 years | |
| Robert Sedor | M | - | 9 years | |
| Monil Shah | M | - |
WindMIL Therapeutics, Inc.
WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Giovanni Caforio | M | 59 | 24 years | |
| Lamberto Andreotti | M | 73 | 19 years | |
| Benjamin Auspitz | M | 51 | - | |
| Iain Dukes | M | 65 | 7 years | |
| Mary Thistle | F | 64 | 2 years | |
| Thomas R. Beck | M | 74 | - | |
| Nicholas Lee Gurreri | M | - |
Transave, Inc.
 Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | - |
| James Cornelius | M | 81 | 10 years | |
| Charles A. Heimbold | M | - | 20 years | |
| Jeffrey Hatfield | M | 66 | 31 years | |
| Peter R. Dolan | M | 68 | 18 years | |
| Blaine Davis | M | 50 | 3 years | |
| Rishi Gupta | M | 46 | - | |
| William Shakespeare | M | 60 | 6 years | |
| Michael Dybbs | M | 49 | 2 years | |
| Timothy Clackson | M | 58 | 2 years | |
| John E. Celentano | M | 64 | 31 years | |
| John M. McAdam | M | 49 | 4 years | |
| Myrtle Potter | F | 65 | 9 years | |
| Timothy G. Whitten | M | 67 |
Transave, Inc.
Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | 2 years |
| Annalisa Jenkins | M | 58 | 3 years | |
| Dee Grosso | F | - |
Transave, Inc.
Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | - |
| Jean Franchi | F | 57 | 2 years | |
| Geoffrey P. Gilmore | M | 58 | 15 years | |
| Charles Rowland | M | 65 | 11 years | |
| Charles Bancroft | M | 65 | 36 years | |
| Tricia Truehart | F | - | 3 years | |
| Sara Garon Berl | F | - | 8 years | |
| Randall W. Whitcomb | M | 69 | 14 years | |
| Jason Haddock | M | 54 | 14 years | |
| Kathy Yi | F | 52 | 3 years | |
| Christine Pellizzari | F | 56 | 8 years | |
| Peter M. Clarke | M | 64 | - | |
| Daniel Abdun-Nabi | M | 69 | 6 years | |
| Brian Daniels | M | 65 | 14 years | |
| Matt Patterson | M | 52 | 6 years | |
| Luke Beshar | M | 65 | 6 years | |
| Arlene Morris | F | 72 | 3 years | |
| James Topper | M | 62 | 11 years | |
| Carl Gordon | M | 59 | 6 years | |
| Ted Love | M | 65 | 8 years | |
| Leif Valdemar Johansson | M | 73 | 13 years | |
| Lewis B. Campbell | M | 77 | 18 years | |
| Béatrice J. Cazala | F | 67 | 32 years | |
| Andrew Shenker | M | 69 | 5 years | |
| Louis J. Freeh | M | 74 | 8 years | |
| Georges Gemayel | M | 64 | 2 years | |
| Michael Rome | M | 39 | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Donald Hayden
- Personal Network